Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;268(8):2666-2670.
doi: 10.1007/s00415-020-10272-0. Epub 2020 Oct 24.

COVID-19 in Parkinson's disease: what holds the key?

R Sainz-Amo  1 , B Baena-Álvarez  2 , I Pareés  2 , G Sánchez-Díez  2 , P Pérez-Torre  2 , J L López-Sendón  2 , S Fanjul-Arbos  2 , E Monreal  2 , I Corral-Corral  2 , N García-Barragán  2 , J C Martínez-Castrillo  2 , A Fasano  3   4 , A Alonso-Cánovas  2
Affiliations

COVID-19 in Parkinson's disease: what holds the key?

R Sainz-Amo et al. J Neurol. 2021 Aug.

Abstract

Introduction: Parkinson's disease (PD) is more frequent in the elderly and increases the risk of respiratory infections. Previous data on PD and SARS-CoV-2 are scarce, suggesting a poor prognosis in advanced disease and second-line therapies.

Methods: A retrospective case-control study comparing patients with PD and COVID-19 and patients with PD without COVID-19 was conducted during the pandemic period in Spain (March 1st-July 31st 2020) in a tertiary university hospital.

Results: Thirty-nine (COVID-19 +) and 172 (COVID-19-) PD patients were included. Fifty-nine percent were males in both groups, with similar age (75.9 ± 9.0 COVID-19 + , 73.9 ± 10.0 COVID-19-), disease duration (8.9 ± 6.2 COVID-19 + , 8.5 ± 5.6 COVID-19-) and PD treatments. COVID-19 was mild in 10 (26%), required admission in 21 (54%) and caused death in 8 (21%) patients. Dementia was the only comorbidity more frequent in COVID-19 + patients (36% vs. 14%, p = 0.0013). However, in a multivariate analysis, institutionalization was the only variable associated with COVID-19 + (OR 17.0, 95% CI 5.0-60.0, p < 0.001). When considering severe COVID-19 (admission or death) vs. mild or absent COVID-19, institutionalization, neoplasm, dementia and a lower frequency of dopamine agonists were associated with severe COVID-19. In multivariate analysis, only institutionalization [OR 5.17, 95% CI 1.57-17, p = 0.004] and neoplasm [OR 8.0, 95%CI 1.27-49.8, p = 0.027] remained significantly associated.

Conclusion: In our experience, institutionalization and oncologic comorbidity, rather than PD-related variables, increased the risk of developing COVID-19, and impacted on its severity. These findings suggest that epidemiologic factors and frailty are key factors for COVID-19 morbidity/mortality in PD. Appropriate preventive strategies should be implemented in institutionalized patients to prevent infection and improve prognosis.

Keywords: COVID-19; Comorbidity; Institutionalization; Parkinson; Prognosis; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

On behalf of all authors, the corresponding author states that there is no conflict of interest. Data are available upon request to the authors.

Figures

Fig. 1
Fig. 1
Frequency of comorbidities in COVID-19- and COVID-19 + groups
See this image and copyright information in PMC

References

    1. World Health Organization Coronavirus Disease (COVID-19) (2020) https://covid19.who.int. Accessed Aug 31, 2020
    1. Chaomin Wu, Chen Xiaoyan, Cai Yanping, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934–943. doi: 10.1001/jamainternmed.2020.0994. - DOI - PMC - PubMed
    1. Monteiro L, Souza-Machado A, Valderramas S, et al. The effect of levodopa on pulmonary function in Parkinson’s disease: a systematic review and meta-analysis. Clin Ther. 2012;2:1049–1055. doi: 10.1016/j.clinthera.2012.03.001. - DOI - PubMed
    1. Prasad S, Holla VV, Neeraja K, et al. Parkinson disease and COVID-19: perceptions and implications in patients and caregivers. Mov Disord. 2020;35:912–914. doi: 10.1002/mds.28088. - DOI - PMC - PubMed
    1. Helmich RC, Bloem BRC The Impact of the COVID-19 pandemic on parkinson disease: hidden sorrows and emerging opportunities. J Parkinsons Dis. 2020;10:351–354. doi: 10.3233/JPD-202038. - DOI - PMC - PubMed